₹61.60 to ₹11,000: Multibagger stock turns ₹1 lakh into ₹1.78 crore in 13 years

Multibagger stock: Stock market investors are always on the lookout for stocks with high return potential, and multibagger stocks are often at the top of their list. However, earning substantial profits from stock investments often requires patience. One such stock that has rewarded investors' patience is Neuland Laboratories.

Neuland Laboratories share price, which is currently trading at ₹11,000 on National Stock Exchange (NSE), has skyrocketed nearly 17,757 per cent in 13 years, rising from ₹61.60 apiece, translating into over 179 times returns during the period.

To put it in perspective, an investment of ₹1 lakh made 13 years ago and held over time would have grown significantly to ₹1.78 crore.

Neuland Laboratories stock movement

Neuland Laboratories share price was trading over 6 per cent lower at ₹10,915 on the NSE on Thursday, February 27, amid a lacklustre market movement.

Neuland Laboratories stock has remained volatile in the last one year. The stock may have enticed long-term investors with its multibagger returns, however, it has failed to impress short-term investors.

In the last six months, Neuland Laboratories share price has fallen over 11 per cent while it has lost 19 per cent in the last one month alone. On a year-to-date (YTD) basis, Neuland Laboratories share price has plunged from ₹14,294 to ₹10,915 per share, losing 23.64 per cent of its value.

Neuland Laboratories financials

Net profit of Neuland Laboratories declined to ₹57.24 crore, marking a 13.3 per cent decrease compared to the average PAT of previous quarters, for the quarter ending on December 31, 2024. The profit before tax (PBT) has decreased to ₹68.07 crore, marking a 19.6 per cent decline compared to the average PBT over the past four quarters.

On a positive note, Neuland Laboratories recorded its highest earnings per share (EPS) in the past five quarters at ₹78.75, signalling increased profitability and greater returns for shareholders. Moreover, the company's debtors turnover ratio improved to 5 times, demonstrating a more efficient debt settlement process.

Neuland Laboratories is engaged in the manufacturing and selling of bulk drugs and caters to both domestic and international markets.

Disclaimer: This story is for educational purposes only. The views and recommendations above are those of individual analysts or broking companies, not Mint. We advise investors to check with certified experts before making any investment decisions.